Chengda Pharmaceuticals (301201.SZ): Dapagliflozin API approved by CDE.

Chengda Pharmaceuticals (301201.SZ) announced that the company has received the approval and issuance of the chemical raw materials for Dapagliflozin by the National Medical Products Administration in the "Chemical Raw Materials Market Application Approval Notice". The related indications for the drug are: on the basis of diet and exercise, this product can be used as a monotherapy for improving blood sugar control in adult patients with type 2 diabetes. This product is not suitable for the treatment of type 1 diabetes or diabetic ketoacidosis.